Optipharm.

At a glance

Optipharm. filed 18 disclosures in the last 12 months, including 4 insider. The most recent key filing was on Sep 18.

Revenue for 2025 was ₩22.3B, up 13.8% on 2024. It made an operating loss of ₩2.4B. Debt was 61% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩11.9B and operating loss of ₩929.5M.

The 2025 annual report lists 79 employees with an average tenure of 6.6 years and average pay of ₩59.9M, #981 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩74M each on average. It paid no cash dividend for 2025. ㈜이지홀딩스 and related parties held 41.00% at year end.

From the 2025 annual report

Staff: 79 (49 men, 30 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩4.7B. Directors and auditors: 5, paid ₩369M in total.

No cash dividend was paid for 2025.

Largest shareholder

㈜이지홀딩스 holds 34.59%; with 14 related parties the group holds 41.00% of common shares at year end (from 40.88% at the start of the year).

Auditor: 광교회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary